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The transcription factor NF-kB regulates the expres-
sion of genes involved in cancer cell invasion, metasta-
sis, angiogenesis, and resistance to chemotherapy. In
normal cells NF-kB is maintained in the cytoplasm by
protein-protein interaction with inhibitor IkBs. In con-
trast, in cancer cells a substantial amount of NF-kB is in
the nucleus and constitutively activates target genes. To
understand the mechanisms of constitutive NF-kB acti-
vation, we have analyzed the function of IkBa and IkBb
in breast cancer cells. In most cases, constitutive NF-kB
DNA binding correlated with reduced levels of either
IkBa or IkBb isoforms. Overexpression of IkBa but not
IkBb1 resulted in reduced constitutive DNA binding of
NF-kB in MDA-MB-231 cells. Unexpectedly, IkBb1 over-
expression moderately increased 12-O-tetradecanoyl-
phorbol-13-acetate- and interleukin-1-inducible NF-kB
DNA binding. 12-O-Tetradecanoylphorbol-13-acetate-
and interleukin-1-induced transactivation by NF-kB,
however, was lower in IkBb1-overexpressing cells. Mu-
tants of IkBb1 lacking the C-terminal casein kinase II
phosphorylation sites, which form a stable complex with
DNA bound NF-kB without inhibiting its transactivation
in other cell types, repressed the transactivation by
NF-kB in MDA-MB-231 cells. Consistent with the results
of transient transfections, the expression of urokinase
plasminogen activator, an NF-kB target gene, was re-
duced in IkBb1-overexpressing cells. These results sug-
gest that depending on the cell type, IkBb1 represses the
expression of NF-kB-regulated genes by inhibiting ei-
ther DNA binding or transactivation function of NF-kB.
Regulation of gene expression by the NF-kB1/Rel family of
transcription factors is controlled mainly by the inhibitory IkB
proteins which include IkBa, IkBb, IkBg, and IkBe (1–4). The
active complex of NF-kB is composed of homodimers and het-
erodimers of p50, RelA, RelB, and c-Rel. These complexes are
sequestered in the cytoplasm by IkBs. Extracellular signal-
induced phosphorylation and subsequent degradation of IkBs
is essential for nuclear translocation of NF-kB. NF-kB binds to
the recognition elements in the promoter region of target genes
and activates transcription. Transactivation by NF-kB involves
interaction with transcriptional coactivators such as CBP/p300
and SRC-1 and general transcription factors including TBP
(5–8). In addition, NF-kB interacts with transcription factors
such as activator protein 1 (AP-1) and serum response factors
and synergistically activates transcription (9, 10).
IkB proteins determine the duration of transactivation by
NF-kB. IkBa is involved in transient activation of NF-kB be-
cause it is degraded rapidly upon stimulation and is resynthe-
sized by activated NF-kB (1–4). Most of the inducers of NF-kB
cause degradation of IkBa. The newly synthesized IkBa se-
questers NF-kB in the cytoplasm and terminates the signal.
IkBb is involved in persistent activation of NF-kB (11). Degra-
dation of IkBb is much more delayed than IkBa and resynthe-
sis is independent of NF-kB (11). Degradation of IkBb is de-
pendent on the cell type and the extracellular signals that
induce NF-kB. For example, whereas interleukin 1 (IL-1) in-
duces degradation of IkBb in most cell types tested, tumor
necrosis factor (TNF-a) induces degradation of IkBb in E29.1 T
cell hybridomas but not in Jurkat cells (11, 12). Together, but
not separately, TNF-a and interferon g induce degradation of
IkBb in PC12 cells (13). The ability of IkBb to repress NF-kB
DNA binding is determined by the basal phosphorylation of the
C-terminal PEST domain (14). The newly synthesized hy-
pophosphorylated IkBb functions as a chaperone for NF-kB by
protecting it from IkBa (15). The IkBbzNF-kB complex enters
the nucleus, binds to DNA, and activates transcription (16, 17).
The phosphorylation of the PEST domain by casein kinase II or
the association of the IkBbzNF-kB complex with high mobility
group I (HMG I) proteins on selected promoters converts IkBb
to a repressor of NF-kB DNA binding activity (14, 17).
Two isoforms of IkBb, b1 and b2, have been described re-
cently (18). These isoforms differ in their C-terminal amino
acids. IkBb1 is functionally similar to IkBa and efficiently
represses the activity of p50:RelA heterodimers. It is found in
both the nucleus and cytoplasm and is degraded by various
stimuli. In contrast, IkBb2 is a cytoplasmic protein that is
refractory to signal-induced degradation. Although both iso-
forms are indistinguishable in their binding preferences to
cellular NF-kB/Rel homo- and heterodimers, IkBb2 is more
effective in inhibiting RelA homodimers than p50:RelA and
p50:c-Rel heterodimers (18). This property of IkBb2 is similar
to that of IkBe which preferentially inhibits the activity of RelA
homodimers (19).
There is increasing evidence for the role of NF-kB in cancer
progression and resistance to chemotherapy (20, 21). Constitu-
tive activation of NF-kB has been observed in Hodgkin’s lym-
phoma, melanomas, juvenile myelomonocytic leukemia, cuta-
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neous T cell lymphoma, and human T cell leukemia virus type
I Tax protein-mediated cellular transformation (22–26). We
and others (27, 28) have shown that NF-kB is constitutively
active in a subset of breast cancers. In this study, we have
investigated the role of IkBa and IkBb in constitutive activa-
tion of NF-kB in breast cancer cells. Constitutive DNA binding
correlated with reduced levels of either IkBa or IkBb. Both
isoforms of IkBb are present in breast cancer cell lines and
primary breast cancers. Overexpressed IkBa but not IkBb1
repressed constitutive DNA binding of NF-kB in MDA-MB-231
cells. IkBb1, in contrast, repressed transactivation by NF-kB.
Unlike in the mouse embryonal carcinoma cell line P19 and the
human embryonic kidney cell line 293, mutants of IkBb1 that
cannot be phosphorylated by casein kinase II efficiently re-
pressed transactivation by NF-kB in MDA-MB-231 cells (17,
29). Taken together, these results reveal a novel cell type-
specific inhibitory regulation of transactivation function but
not DNA binding of NF-kB by IkBb1.
EXPERIMENTAL PROCEDURES
Cell Culture—All breast cancer cell lines were purchased from
ATCC, and their growth conditions have been described previously (30).
1029 M insulin was added to MDA-MB-231 and its clones during long
term culturing.
Recombinant Plasmids—NF-kB/CAT reporter gene, human IkBa,
and mouse IkBb expression vectors have been described previously (27).
The AP-1/CAT reporter was a generous gift of E. O’Neill (Merck) and
contains three copies of an AP-1 site from the human metallothionein
gene (31). Human IkBb and its mutants were generous gifts from D.
Ballard (Vanderbilt University, Nashville, TN) and were described
previously (29). mIkBb1DC, which lacks 50 amino acids at the C-
terminal, was generated by cloning a NotI-HindIII fragment of mIkBb1
to the pcDNA3 expression vector (Invitrogen). Retrovirus constructs
containing hIkBa and mIkBb1 coding sequences were prepared by
cloning cDNAs into the respective EcoRI and NotI sites of the modified
retrovirus vector LxSN (32).
Retrovirus Preparation and Transduction—LxSN vectors were am-
photrophically packaged into the AM12 packaging cell line (33), and the
cell-free supernatant was used to transduce MDA-MB-231 cells as
described previously (34). Vector containing clones were isolated by
growing cells in G418 (1 mg/ml).
Electrophoretic Mobility Shift Assay (EMSA)—Whole cell extracts
from cells were prepared and subjected to EMSA as described previ-
ously (27). Densitometric analysis was performed to classify constitu-
tive DNA binding activity.
Western Blotting—Cell extracts were prepared in radioimmunopre-
cipitation assay buffer (35) and subjected to Western blotting as recom-
mended by the antibody manufacturers (Santa Cruz Biotechnology and
Sigma). For quantitation, autoradiograms were scanned using a
densitometer.
DNA Immunoprecipitation—Nuclear extracts were prepared as de-
scribed previously (36). Nuclear extracts supplemented with 1% Non-
idet P-40 were precleared in insoluble protein A solution (Sigma) and
subjected to EMSA reaction. Antibodies (0.2 mg) were added, and incu-
bation was carried out for 1 h on ice. Protein A-agarose (20-ml bead
volume) was added, and the reaction mixture was incubated for 1 h at
4 °C with gentle rocking. Protein A-agarose was collected by centrifu-
gation, washed five times in 13 EMSA buffer (10 mM Tris-HCl, 0.5 mM
EDTA, 100 mM KCl, 10% glycerol, 0.5 mM dithiothreitol, 0.5 mM phen-
ylmethylsulfonyl fluoride, and 0.2% Nonidet P-40), and subjected to
SDS-polyacrylamide gel electrophoresis. The amount of radioactive
DNA immunoprecipitated with the antibody complex was visualized by
autoradiography and quantitated by densitometric scanning.
Transient Transfections and CAT Assays—Transient transfections
and the CAT assay have been described previously (27). Statistical
analysis was performed using Statview software (version 4.1; Abacus
FIG. 1. Differential expression of IkBa, IkBb1, and IkBb2 in
breast cancer cells. A, DNA binding activity of NF-kB in breast
cancer cell lines. Whole cell extracts (6 mg) were incubated with double-
stranded oligonucleotide containing NF-kB, SP1, or CTF/NF-1-binding
sites and subjected to EMSA. CTF/NF-1 displays multiple bands due to
alternative splicing. B, RelA and IkB expression in breast cancer cell
lines. Whole cell extracts (50 mg) from indicated cell lines were analyzed
for RelA, p105/p50, and IkBs by Western blotting. For identification of
IkBb1, an antibody raised against the unique C-terminal region of
IkBb1 was used in Western blotting. Integrity of proteins in each lanes
was verified by reprobing the blot with antibody against a-tubulin.
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Concepts, Berkeley, CA). Data were evaluated by one-factor analysis of
variance and Fisher’s protected least significant difference as a post hoc
test.
Serum and Epidermal Growth Factor (EGF) Treatment and North-
ern Blotting—For serum stimulation, cells were maintained in MEM
without serum for 48 h. MEM with 10% fetal calf serum was added, and
the cells were harvested after 4 h. For EGF treatment, cells were
maintained in MEM (without fetal calf serum) for 48 h. EGF (30 ng/ml)
was added, and cells were harvested after 4 h. RNA was prepared by the
guanidinium isothiocyanate/cesium chloride method and subjected to
Northern blotting as described previously (30).
RESULTS
Differential Expression of IkBs in Breast Cancer Cells—Con-
stitutive NF-kB DNA binding activity in several breast cancer
cell lines was compared with the expression level of IkBa and
IkBb (Fig. 1 and Table I). MCF-7, T47-D, and MDA-MB-157
cells displayed the least amount of NF-kB DNA binding and
higher levels of IkBa and IkBb compared with other cell lines
(see “Experimental Procedures”). In comparison, NF-kB DNA
binding activity in other cell lines were either high (MDA-MB-
231, MDA-MB-435, MDA-MB-436, MDA-MB-468, and HBL-
100) or intermediate (ZR-75–1, SK-BR-3, and Hs578T) (Fig. 1A
and Table I). Among these cell lines, MCF-7, T47-D, and ZR-
75–1 express estrogen receptor a (ERa) and are more differen-
tiated than other cell lines (37). Most of the cell lines that
displayed elevated NF-kB DNA binding activity are ERa-neg-
ative, consistent with our previous report (27). In contrast to
NF-kB, DNA binding of SP1 and CTF/NF-1 family transcrip-
tion factors did not correlate with ERa status (Fig. 1A). The
NF-kB complex is a heterodimer of RelA and p50 subunits as
determined by antibody supershift assays (data not shown). In
general, NF-kB DNA binding activity correlated inversely with
the levels of IkBa, IkBb1, and IkBb2 (Fig. 1B, Table I). For
example, higher NF-kB DNA binding correlated with reduced
levels of either IkBa (MDA-MB-435 and MDA-MB-468), IkBb2
(MDA-MB-436) or IkBa, or IkBb1 and IkBb2 (MDA-MB-231).
IkBb2 is the major IkBb in breast cancer cell lines with the
exception of HBL-100 and MDA-MB-436 cells which contained
similar levels of IkBb1 and IkBb2. Reverse transcription-poly-
merase chain reaction was used to confirm the presence of
transcripts corresponding to IkBb1 and IkBb2 in breast cancer
cells (data not shown). Proteins corresponding to IkBb1 and
IkBb2 were also observed in primary breast cancers (data not
shown). There was no correlation between IkB expression and
NF-kB DNA binding activity in Hs578T and HBL-100 cells.
Despite reduced levels of both IkBa and IkBb2, NF-kB DNA
binding was intermediate in Hs 578T. It is possible that this
cell line overexpresses other IkB proteins. HBL-100 cells dis-
played elevated NF-kB DNA binding activity despite the pres-
ence of IkBa and IkBb2. Whether elevated NF-kB DNA binding
in this cell line is due to 1:1 ratio of IkBb1 and IkBb2 or due to
reduced levels of other IkB proteins is not known. Constitutive
NF-kB DNA binding activity did not correlate with elevated
levels of RelA and p50 proteins (Fig. 1B).
The Effect of IkBa and IkBb1 Overexpression on Constitutive
NF-kB DNA Activity in MDA-MB-231 Cells—To determine the
role of IkBa and IkBb in constitutive NF-kB activation, we
generated MDA-MB-231 cells overexpressing IkBa and IkBb1.
The levels of IkBa and IkBb1 in cells transduced with empty
retrovirus (LxSN3), IkBa coding retrovirus (IkBa3–7), and
IkBb1 containing retrovirus (IkBb21–25) were determined by
Western blotting (Fig. 2A). Two clones containing vector alone
(called LxSN3 and LxSN5 cells hereafter), two clones with
IkBa (IkBa5 and IkBa7 cells), and three clones with IkBb1
(IkBb21, IkBb22, and IkBb23) were chosen arbitrarily for this
study. NF-kB DNA binding activity in these clones is shown in
Fig. 2B. IkBa overexpression resulted in reduced constitutive
DNA binding (compare lane 1 and 2 with lanes 3 and 4).
Unexpectedly, constitutive NF-kB DNA binding was the same
in IkBb cells and LxSN cells (compare lanes 1 and 2 with lanes
5–7). Similar results were obtained when nuclear extracts in-
stead of whole cell extracts were used (Fig. 2B, lanes 8–14).
Also, a similar binding pattern was obtained with PRDII ele-
ment (NF-kB-binding site in the interferon-b gene promoter
which is flanked by the HMG I protein-binding site) and the
NF-kB-binding site of urokinase plasminogen activator (uPA)
promoter (data not shown). The DNAzNF-kB complex is a het-
erodimer of p50 and RelA as antibodies against both proteins
supershifted the complex (data not shown). IkBa or IkBb over-
expression did not affect DNA binding of AP-1 (Fig. 2B, lower
panel).
As stated earlier, the hypophosphorylated IkBb1 enters the
nucleus and forms a stable complex with DNA-bound NF-kB.
Inability of IkBb1 to reduce NF-kB DNA binding activity could
be due to unimpaired interaction of the IkBb1zNF-kB complex
with DNA. To address this possibility, we performed DNA
immunoprecipitation assays with nuclear extracts from
LxSN3, IkBa5, and IkBb21 cells. Radiolabeled DNAzNF-kB
complexes were immunoprecipitated with either RelA anti-
body, IkBa antibody, or IkBb antibody. Antibody against neu
oncogene was used as a negative control. DNAzNF-kB complex
was efficiently immunoprecipitated by RelA antibody (Fig. 2C,
lanes 1, 5, and 9). The amount of DNAzNF-kB complex immu-
noprecipitated by RelA antibody was similar to the amount of
NF-kBzDNA complex identified in EMSA. Neither IkBa anti-
body nor neu antibody immunoprecipitated DNAzNF-kB com-
plex from nuclear extracts (lanes 2, 4, 6, 8, 10, and 12). IkBb
antibody immunoprecipitated radiolabeled probe from only
IkBb21 cells (compare lanes 3, 7, and 11). These results indi-
cate that IkBb1 either binds directly to the NF-kB-binding site
or forms a stable complex with DNA-bound NF-kB. Whatever
the mechanism involved, DNA binding of IkBb1 did not inter-
fere in DNA-NF-kB interaction. IkBb1-DNA interaction was
TABLE I
Summary of NF-kB DNA binding activity and IkB expression in breast cancer cell lines
ERa status in these cell lines has been described previously (30, 37). A value of 41 is assigned to the most intense signal among various cell lines.
ERa NF-kB IkBa IkBb1 IkBb2
MCF-7 1 1 1111 1 111
T47-D 1 1 1111 11 111
ZR-75 1 11 11 11 111
MDA-MB-231 2 111 11 1 1
MDA-MB-435 2 111 1 11 1111
MDA-MB-157 2 1 111 11 111
MDA-MB-436 2 1111 111 111 1
MDA-MB-468 2 111 1 1111 1111
SK-BR-3 2 11 1111 11 111
Hs578T 2 11 1 11 1
HBL100 2 1111 1111 111 111
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not observed in antibody supershift assays possibly due to the
unstable nature of the complex under electrophoresis condi-
tions (data not shown).
Inducible DNA Binding of NF-kB in Cells Overexpressing
IkBa and IkBb—To investigate the effect of IkBa and IkBb on
inducible DNA binding of NF-kB, we performed EMSA with
extracts from cells treated with either TPA or IL-1b for 1 h.
Inducible NF-kB DNA binding activity was lower in IkBa cells
compared with other cells (Fig. 3A). As with constitutive DNA
binding, IkBb failed to inhibit inducible NF-kB DNA binding.
In fact, we consistently observed higher DNA binding in TPA-
treated IkBb cells compared with other cells (compare lanes 2,
5, 14, 17, and 20). IkBa and IkBb overexpression did not affect
DNA binding of AP-1 (Fig. 3A, lower panel).
To determine whether IkBa and IkBb overexpression alters
the time course of NF-kB activation, EMSA was performed
with the extracts from cells treated with TPA and IL-1 for
specific intervals. TPA-inducible DNA binding activity was ob-
served after 60 min of stimulation in all three cell types (Fig.
3B, compare lanes 4, 13, and 22) and started to decline after 3 h
of stimulation. We consistently observed increased NF-kB DNA
binding activity in TPA-treated IkBb cells compared with other
cells. There was no cell type-specific variation in the rate of
IkBa degradation. Approximately 50% of IkBa was present at
60 min and 2 h after TPA addition, and its level increased at 3 h
(Fig. 3B). NF-kB DNA binding activity at 6, 9, and 24 h after
TPA addition was higher than in untreated cells which corre-
lated with reduced levels of IkBa. Degradation of IkBb1 was
minimal (,25%) which was evident at 2 and 3 h post-stimula-
tion. We next examined the time course of IL-1-induced NF-kB
DNA binding activity (Fig. 3C). NF-kB DNA binding increased
within 30 min of IL-1 addition in all three cell types. There was
a difference in the termination of inducible DNA binding. In
LxSN5 and IkBa5 cells, maximum DNA binding was observed
after 1 h of IL-1 addition and returned almost to basal levels by
2 h. In contrast, in IkBb21 cells, a substantial level of inducible
DNA binding persisted after 2 h of IL-1 addition. Similar re-
sults were obtained with three other IkBb-overexpressing
clones (data not shown). As with TPA-treated cells, IkBa deg-
radation occurred at a similar rate in all three cell types, and
partial degradation of IkBb (,30%) coincided with induction of
NF-kB DNA binding in IkBb21 cells (data not shown). Taken
together, our results demonstrate that although IkBa did in-
hibit constitutive DNA binding, neither IkBa nor IkBb1 had
much effect on inducible DNA binding of NF-kB in MDA-MB-
231 cells.
Activity of NF-kB- and AP-1-dependent Promoters in IkBa-
and IkBb1-overexpressing Cells—The inability of IkBb1 to re-
press constitutive DNA binding of NF-kB was unexpected.
However, it is possible that IkBb1 may convert the NF-kBzDNA
complex to a transcriptionally inactive complex similar to ret-
inoblastoma protein-induced inactivation of the NF-kBzDNA
complex (38). To address this possibility, we performed tran-
sient transfection experiments using an NF-kB-dependent CAT
reporter gene (NF-kB/CAT, see Ref. 27). Expectedly, constitu-
tive and inducible activities of the NF-kB/CAT were lower in
IkBa cells compared with LxSN cells (Fig. 4A). Interestingly,
inducible activities of NF-kB/CAT, particularly with IL-1, were
lower in IkBb cells. The NF-kB/CAT reporter gene expression
requires the binding site for NF-kB because a similar reporter
in which the NF-kB-binding site has been mutated is inactive
in MDA-MB-231 cells (27).
As stated in the Introduction, NF-kB interacts with AP-1,
and this interaction results in synergistic activation of tran-
scription. Because IkBb1 inhibited NF-kB-dependent gene ex-
pression despite efficient DNA binding, it is possible that
IkBb1 in the NF-kBzDNA complex prevents synergistic inter-
action with AP-1 either due to a conformational change or
steric hindrance. We measured constitutive and TPA-inducible
activity of AP-1/CAT reporter gene in all cell lines. Similar
levels of constitutive and TPA-inducible activity were observed
in LxSN5, IkBa5, and IkBa7 cells (Fig. 4B). Due to differences
in cell passage number, we consistently observed lower consti-
tutive and TPA-inducible activities in LxSN3 cells. These cells
were passed ;15 more times than other clones. For unknown
reasons, decreasing levels of AP-1 transcriptional activation
with increasing cell passage were consistently observed with
this cell line. The constitutive and TPA-inducible activities of
FIG. 2. Overexpression of hIkBa and mIkBb1 in MDA-MB-231
cells. A, IkBa and IkBb1 in transduced clones. Whole cell extracts from
individual G418-resistant clones of MDA-MB-231 cells were subjected
to Western blotting using indicated antibodies. B, NF-kB DNA binding
activity in IkBa- and IkBb1-overexpressing cells. Whole cell extracts (6
mg, lanes 1–7) or nuclear extracts (10 mg, lanes 8–14) from vector alone
(LxSN3 and LxSN5), IkBa-overexpressing (IkBa5 and IkBa7), or
IkBb1-overexpressing (IkBb21, IkBb22, and IkBb23) cells were sub-
jected to EMSA with either NF-kB probe (top panel) or AP-1 probe
(bottom panel). C, IkBb1 is associated with NF-kB-binding site contain-
ing probe. An EMSA reaction with radiolabeled NF-kB probe was per-
formed with 15 mg of nuclear extracts from indicated clones. EMSA
reactions were subjected to immunoprecipitation using indicated anti-
bodies. Antibodies against RelA and neu served as positive and negative
controls, respectively. The amount of radioactive probe precipitated by
RelA antibody from LxSN3 cells was set as 100%, and the relative
difference is indicated.
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AP-1 were reproducibly lower (n 5 6) in IkBb cells compared
with other clones. Similar results were obtained with interleu-
kin-11 (IL-11) promoter/CAT reporter with an AP-1-binding
site (data not shown). The activity of the reporter gene is
AP-1-dependent since an IL-11/CAT reporter in which the AP-
1-binding site is mutated was inactive (data not shown). To
confirm these results further, we performed transient transfec-
tion assays with AP-1/CAT reporter, RelA, and IkB expression
vectors in MDA-MB-231 cells. Because of a higher level of basal
AP-1 activity, only a modest increase in AP-1/CAT activity in
RelA-transfected cells was observed (Fig. 4C). Both IkBa and
IkBb inhibited RelA-mediated increases in AP-1/CAT activity.
PEST Domain Mutants of IkBb Inhibit NF-kB Activity in
MDA-MB-231 Cells—Recent studies have indicated that the
hypophosphorylated form of IkBb forms a stable complex with
DNA-bound NF-kB (14, 15, 29). Phosphorylation of Ser-313 and
Ser-315 of IkBb by casein kinase II results in the release of
both IkBb and NF-kB from DNA and, consequently, reduced
transactivation in P19 and 293 cells (17, 29). Alternatively,
promoter context-dependent interaction of HMG I with the
IkBbzNF-kBzDNA complex results in the release of NF-kB and
IkBb from DNA (17). Neither of the above two mechanisms
appears to be responsible for reduced NF-kB/CAT activity in
IkBb1-overexpressing MDA-MB-231 cells because transactiva-
tion function but not the DNA binding of NF-kB was inhibited
by IkBb1 in these cells. To verify this further, we compared the
ability of wild type and mutants of IkBb (in which casein kinase
II phosphorylation sites have been mutated to alanine or as-
partic acid) to repress NF-kB DNA binding activity in MDA-
MB-231 and 293 cells. The effect of IkBb1 expression vector
lacking 50 amino acids at the C terminus (mIkBb1DC which
lacks casein kinase II phosphorylation sites) on NF-kB DNA
FIG. 3. Inducible DNA binding of
NF-kB in IkB-overexpressing cells. A,
TPA- and IL-1b-inducible DNA binding
activity. Whole cell extracts from un-
treated (2), TPA-treated (125 nM), or IL-
1b-treated (2.5 ng/ml) cells were sub-
jected to EMSA with either NF-kB probe
(top panel) or AP-1 probe (bottom panel).
B, time course of TPA-inducible NF-kB
DNA binding activity. Whole cell extracts
were prepared at specific intervals after
treatment with TPA and subjected to
EMSA (top panel). IkBa in all cell types
and IkBb1 in IkBb21 cells were analyzed
by Western blotting. Western blot with
LxSN5 cell extracts was exposed three
times longer than other blots, and it was
performed with double the amount of pro-
teins. As a loading control, the same blots
were reprobed with an antibody against
a-tubulin. C, time course of IL-1-inducible
NF-kB DNA binding activity. The experi-
ments were performed as in B.
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binding activity was also tested in parallel. Wild type but not
the mutants of IkBb1 repressed NF-kB DNA binding activity in
293 cells, which is consistent with previously published data
(Fig. 5A). In contrast, both wild type and mutant IkBb1 failed
to repress NF-kB DNA binding in MDA-MB-231 cells. The
C-terminal serines of IkBb1 appear to be phosphorylated in
both cell types as the mutant proteins with either serine to
alanine or serine to aspartic acid substitution displayed faster
mobility than wild type IkBb1 on an SDS-polyacrylamide gel
electrophoresis (Fig. 5A). We next compared the ability of wild
type and mutant IkBb1 to repress transactivation function of
NF-kB in transient transfection assays. Mutants were as effi-
cient as wild type IkBb1 in repressing NF-kB activity (Fig. 5B).
MDA-MB-231 cells stably expressing mIkBb1DC were gener-
ated to confirm further these results (Fig. 5C). A new clone
containing vector alone was also prepared so that all clones
were of the same passage number. mIkBb1DC overexpression
did not affect constitutive NF-kB DNA binding activity (Fig.
5C). As with the transient transfection assays, however, NF-
kB/CAT activity was reduced in clones overexpressing
IkBb1DC (Fig. 5D). Taken together, these results suggest that
phosphorylation of IkBb1 by casein kinase II is not essential for
repression of NF-kB activity in MDA-MB-231 cells.
Serum and EGF-inducible Expression of uPA in IkBa and
IkBb-overexpressing Cells—Multiple transcription factors in-
cluding AP-1, NF-kB, and the Ets are involved in constitutive
and inducible expression of the uPA gene (39, 40). If the effect
of IkBb on NF-kB- and AP-1-dependent gene expression ob-
served in transient assays is relevant to endogenous gene ex-
pression, IkBb overexpression should inhibit uPA gene expres-
sion. Serum and EGF were used as inducible agents as both can
induce the activity of AP-1 and NF-kB (41, 42). The basal
expression level of uPA was consistently lower in LxSN3 com-
pared with LxSN5, possibly due to the difference in passage
number (Fig. 6). Both constitutive and inducible expression of
uPA was reproducibly lower in IkBa and IkBb cells (Fig. 6, A
and B). In general, the inducible expression was lower in IkBb
cells compared with IkBa cells. Similar results were also ob-
tained with cells overexpressing IkBb1DC (Fig. 6C). The effect
of EGF and serum on AP-1 and NF-kB is mostly at the level of
transactivation as DNA binding of both transcription factors
was not significantly affected upon EGF and serum treatment
(data not shown). These results further emphasize that IkBb1
can repress transcription without interfering with the DNA
binding of NF-kB in MDA-MB-231 cells.
uPA Expression in Breast Cancer Cell Lines—The above re-
sults indicate that NF-kB plays an important role in uPA
expression in breast cancer cells. To extend this observation
further, we compared uPA expression with constitutive NF-kB
DNA binding activity in various breast cancer cell lines. uPA
expression was observed only in cell lines that contained either
intermediate or higher levels of constitutive NF-kB activity
(Fig. 7). Interestingly, uPA expression in three out of five cell
lines correlated with reduced levels of IkBb (MDA-MB-231,
MDA-MB-436, and Hs578T). These results suggest that for
optimum activation of NF-kB-regulated genes, constitutive
NF-kB DNA binding should be accompanied by reduced levels
of IkBb1.
DISCUSSION
Members of the Rel family of transcription factors are usu-
ally sequestered in the cytoplasm by IkB proteins. Several
recent studies have indicated that IkB-mediated cytoplasmic
retention of NF-kB is altered during cancer progression. Al-
though reduced levels of IkB proteins may be responsible for
nuclear NF-kB in some cells, constitutive NF-kB DNA binding
has also been observed under conditions where IkBa is abun-
FIG. 4. Constitutive and inducible activity of NF-kB- and AP-
1-dependent promoters in IkB-overexpressing clones. A, activity
of NF-kB-dependent promoter. NF-kB/CAT reporter (5 mg) was trans-
fected along with an internal control plasmid coding for b-galactosidase
into indicated cells. Cells were treated with either TPA (125 nM) or
IL-1b (2.5 ng/ml) 24 h after transfection. CAT activity in equal number
of b-galactosidase units was measured 48 h after transfection. Consti-
tutive NF-kB/CAT activity in LxSN5 was set arbitrarily as 10 units, and
the relative difference is shown. The mean and standard deviations
from four experiments are shown. Basal, TPA- and IL-1-inducible
NF-kB activities were significantly lower in IkBa- and IkBb1-overex-
pressing cells compared with LxSN cells (p , 0.0005). B, activity of
AP-1-dependent promoter. AP-1/CAT (20 mg) was transfected into indi-
cated clones, and the CAT activity was measured as above. Basal and
TPA-inducible AP-1 activities were significantly lower in IkBb1 cells
compared with other cells (p , 0.0019). M, untreated; f, TPA; p, IL-1.
C, RelA increases AP-1/CAT activity. MDA-MB-231 cells were trans-
fected with 10 mg of AP-1/CAT and indicated expression vectors. The
amount of expression vector was kept constant in all transfections by
substituting with the empty expression vector pcDNA3. Repression of
RelA induced NF-kB activity by IkBs was statistically significant (p ,
0.0018) except in cells transfected with 0.5 mg of IkBa.
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dant (24, 43). Tyrosine phosphorylation-mediated inactivation
without degradation of IkBa or accumulation of hypophospho-
rylated IkBb which transports NF-kB to the nucleus may ac-
count for constitutive NF-kB DNA binding in cells with IkBa
(15, 43). This study was initiated to understand the mecha-
nisms of constitutive NF-kB activation in breast cancer cells.
Constitutive NF-kB DNA binding was observed in cells that
contained reduced level of IkBa (MDA-MB-435 and MDA-MB-
468), IkBb2 (MDA-MB-436), or both IkBa and IkBb (MDA-MB-
231). Expectedly, overexpression of IkBa could reverse consti-
tutive NF-kB DNA binding in MDA-MB-231 cells. However, it
was unexpected that overexpressed IkBb1 cannot inhibit
NF-kB DNA binding in MDA-MB-231 cells even though it could
efficiently repress NF-kB DNA binding in 293 cells (Fig. 5A, see
also Ref. 29). The mechanisms responsible for the cell type-
specific function of IkBb1 is not known. Simeonidis et al. (44)
FIG. 5. Inhibition of NF-kB activity
by PEST domain mutants of IkBb1. A,
effect of PEST domain mutants of IkBb1
on DNA binding of NF-kB in MDA-MB-
231 and 293 cells. Cells (5 3 105) were
transfected with 10 mg of the indicated
expression vectors. Whole cell extracts
were prepared after 48 h of transfection
and subjected to EMSA (top panel) and
Western blotting (bottom panel). mIkBb1
and mIkBb1DC could not be detected in
Western blots. Note the faster mobility of
PEST domain mutants compared with
wild type IkBb1. B, PEST domain mu-
tants of IkBb1 are as efficient as wild type
IkBb1 in repressing NF-kB-dependent
promoter activity. MDA-MB-231 cells
were transfected with the NF-kB/CAT re-
porter gene (5 mg) and an indicated ex-
pression vector. The amount of expression
vector was kept constant in all transfec-
tions by substituting with the empty ex-
pression vector pcDNA3. CAT activity
was measured 48 h after transfection. C,
generation of stable MDA-MB-231 cells
expressing mIkBb1DC. Stable cell lines
were generated by retrovirus-mediated
gene transfer. The expression level of
transduced gene and its effect on NF-kB
DNA binding activity were measured by
Western blotting and EMSA, respec-
tively. D, activity of NF-kB/CAT in
IkBb1DC-expressing cells. Transfection
and CAT assays were as in Fig. 4.
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have shown that the strength by which different IkBs inhibit
NF-kB activity correlates with their ability to sequester NF-kB
in the cytoplasm rather than their ability to inhibit DNA bind-
ing of NF-kB. They have also shown that the first three of six
ankarin repeats determine the cytoplasmic retention potential
of IkBs, whereas the last three ankarin repeats and the C-
terminal PEST sequences determine the ability of IkBs to
inhibit DNA binding. IkBb1 could neither prevent nuclear
translocation nor prevent DNA binding of NF-kB in MDA-MB-
231 cells (Fig. 2 and Fig. 5). IkBb1 was, however, able to inhibit
transactivation by NF-kB in these cells. Phosphorylation of
PEST domain of IkBb1 by casein kinase II (which is required
for inhibition of DNA binding (16, 17)) is not necessary for
repression of transactivation function of NF-kB by IkBb1 in
MDA-MB-231 cells. We observed similar degrees of repression
of NF-kB activity by wild type and mutant IkBb1 lacking
casein kinase II phosphorylation sites (Fig. 5). These results
suggest that IkBb1 contains additional functional domains
which only inhibit the transactivation function of NF-kB. De-
tailed mutational analysis and domain swapping with other
IkBs is essential for characterization of this domain. We have
not directly tested whether this function of IkBb1 is promoter
context-dependent. In this regard, note that IkBb1 reduced the
expression of uPA and the transiently transfected reporter
gene but failed to prevent the resynthesis of IkBa (which is
dependent on NF-kB) in cells treated with TPA (Fig. 3 and Fig.
6). Because the NF-kB-binding site in the reporter gene and
uPA gene lacks the binding sites for HMG I, the repression of
NF-kB activity is not likely due to the interaction of HMG I
with NF-kB-IkBb-DNA.
IkBb may inhibit transactivation by NF-kB independent of
its interaction with NF-kB or through its association with
DNA-bound NF-kB. IkBb1 may sequester a coactivator(s)
which is essential for transactivation by NF-kB. In this regard,
proteins distinct from the IkB/NF-kB family have been shown
to interact with IkBb1 (45, 46). IkBb1 in the NF-kBzDNA com-
plex may inhibit transactivation in the following ways. (i)
IkBb1 may mask the region of RelA which undergoes a modi-
fication such as phosphorylation after DNA binding. Several
recent studies have suggested that RelA phosphorylation is
required for efficient transactivation. For example, Bergmann
et al. (47) have demonstrated that inhibitors of phosphatidyl-
choline-specific phospholipase C and protein kinase C blocked
transactivation by NF-kB after TNF and IL-1b treatment even
though these inhibitors did not block nuclear translocation.
Similarly, Yoza et al. (48) have demonstrated that activation of
the protein-tyrosine kinase pathway is required for lipopolysac-
charide-mediated NF-kB activation but not nuclear transloca-
tion. Phosphorylation of RelA by kinases activated by TNF-a
and ras oncogene has also been reported (49, 50). RelA appears
to be the target of protein kinase A or casein kinase II following
degradation of IkBs (51, 52). Protein kinase A-mediated phos-
phorylation by RelA is required for unmasking of intramolec-
ular interaction sites and subsequent interaction of RelA with
FIG. 6. Effect of IkBa and IkBb overexpression on uPA expres-
sion. A, serum-inducible expression of uPA. Total RNA (20 mg) from
indicated clones maintained in serum-free medium for 48 h (2) or
treated for 4 h with 10% serum-containing media after serum starva-
tion (1) was subjected to Northern blotting using a uPA probe. Integrity
of the RNA was examined by reprobing the blot with ribosomal protein
gene 36B4 (30). The ratio between uPA and 36B4 was determined by
densitometric scanning of autoradiograms. Results from a representa-
tive experiment are shown. B, EGF-inducible expression of uPA. Total
RNA from untreated (2) or EGF-treated (30 ng/ml for 4 h) was sub-
jected to Northern blotting as above. C, serum and EGF-inducible
expression of uPA in cells overexpressing mIkBb1DC.
FIG. 7. Expression of uPA in breast cancer cell lines. uPA ex-
pression was measured by Northern blotting.
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coactivator p300/CBP (53). It is possible that phosphorylation
by protein kinase A and other kinases and/or coactivator-
NF-kB interaction is inefficient when IkBb1 is present in the
NF-kBzDNA complex. (ii) IkBb has been shown to interact with
nuclear receptors including thyroid hormone receptors and ret-
inoid-X receptors (45, 46). Because nuclear receptors such as
estrogen receptor, progesterone receptors, and peroxisome pro-
liferator receptors have been shown to inhibit NF-kB activity,
IkBb1 in the NF-kBzDNA complex may recruit retinoid-X re-
ceptors:peroxisome proliferator receptor heterodimers to the
NF-kBzDNA complex and inhibit transactivation by NF-kB (27,
54–56). (iii) IkBb1 may inhibit synergistic interaction of NF-kB
with other transcription factors including AP-1. We have pro-
vided some evidence for the last possibility. Synergistic cross-
talk between NF-kB and AP-1 is essential for anchorage-inde-
pendent growth of immortalized keratinocytes (57). Inhibitors
of both NF-kB and AP-1 block tumor promoter-induced trans-
formation (58), suggesting the importance of cross-talk in can-
cer progression. We suspect that such cross-talk is more pro-
nounced in cancer cells lacking IkBb1. These cells will be more
responsive to growth factors and serum. Consistent with this
possibility, serum and EGF-inducible expression of uPA was
more pronounced in cells lacking IkBb1. We have observed
increased uPA expression in most of the breast cancer cell lines
that contain constitutively active NF-kB. uPA is absolutely
required for intravasation, the most important step in the
multistep process of tumor metastasis (59), and its overexpres-
sion in breast cancer cells is associated with poor prognosis
(60). In summation, our results suggest that IkBb regulates
NF-kB activity in a cell type-specific manner which determines
whether constitutive DNA binding of NF-kB leads to overex-
pression of NF-kB-regulated genes such as uPA.
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